This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
DMRTA2 / Doublesex- and mab-3-related transcription factor A2 · Western blot design guide
Design a Western Blot for DMRTA2
Source-linked DMRTA2 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-DMRTA2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled October 2026 · For research use; verify linked source records and product datasheet before use
DMRTA2 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~53.4 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | — | |
| Caveat | — | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 1 isoform(s) |
Section 1
Source-Linked DMRTA2 Western Blot Protocol Options
The A13203 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | Target-positive lysate and matched negative control (standard starting point) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A13203; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected DMRTA2 Western Blot Band Size?
DMRTA2 is predicted at 53.4 kDa; nuclear localization may affect recovery, but the supplied features do not demonstrate a migration shift.
| Band near 53.4 kDa | Consistent with the predicted size of full-length DMRTA2; confirm identity with controls. |
| Band near 53.4 kDa enriched in nuclear fraction | Consistent with DMRTA2 nuclear localization. |
| Weak band near 53.4 kDa in whole-cell lysate | Nuclear fractionation may improve detection of DMRTA2. |
| Additional bands away from 53.4 kDa | Their identity is not established by the supplied features. |
💡Expected DMRTA2 appearanceFull-length DMRTA2 has a predicted mass of 53.4 kDa; no empirical band size is supplied, so confirm any candidate band with ordinary identity controls.
| UniProt predicted molecular weight | Sets a 53.4 kDa reference for full-length DMRTA2. |
| Full-length 542-residue sequence | Defines the polypeptide represented by the predicted mass. |
| Calculated mass of 53,356 Da | Expresses the same predicted mass more precisely, without establishing gel migration. |
| Full-length mass reference | Does not establish a separate mature or cleaved band size. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Nuclear DMRTA2 may be poorly recovered in the preparation. | Check nuclear extraction and compare a nuclear fraction. |
| Weak or no signal | Low target recovery or insufficient antibody sensitivity. | Check sample loading and use a validated positive control. |
| Band higher than expected | The supplied features do not establish a size-increasing modification or assembly. | Verify identity with an independent antibody or DMRTA2 depletion. |
| Band lower than expected | The supplied features do not establish a smaller isoform or processed product. | Check sample integrity and verify identity with DMRTA2 depletion. |
| Multiple bands | The supplied features do not establish multiple resolvable DMRTA2 forms. | Compare bands using an independent antibody or DMRTA2 depletion. |
Experiment evidence
Western blot images showing DMRTA2 band
A13203 · DMRTA2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for DMRTA2 Western blot
🧪For positive controls for DMRTA2 in Western blot, you can use an independently validated DMRTA2-expressing sample; no HPA positive tissue or cell is supplied.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: HPA provides no expression data, so suitable positive and negative samples require independent validation.
HPA tissue expression evidence for DMRTA2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced DMRTA2 Western Blot Tips
Deeper troubleshooting and optimisation questions for DMRTA2, answered from its protein features.
How should DMRTA2 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could DMRTA2 isoforms produce multiple bands?
Isoforms · The supplied record lists one isoform and no alternative sequence. It does not provide an isoform-based explanation for multiple bands.
Do annotated modifications prove a band shift?
PTM · The linked UniProt record describes protein features. A modification annotation alone does not demonstrate a visible shift; retain any condition or experimental qualifier attached to it.
Does this guide establish induction of DMRTA2?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for DMRTA2?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A13203 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should DMRTA2 bands be quantified across samples?
Quantitation · Compare the same candidate band across consistently prepared samples, preferably using the same nuclear fraction. The predicted 53.4 kDa mass helps locate a candidate band but does not establish its identity.
Where should DMRTA2 appear on a Western blot?
Interpretation · DMRTA2 has a predicted mass of 53.4 kDa. No observed band position is supplied, so treat this as a reference for identifying a candidate band, not a guaranteed apparent mass.
The supplied features list no modified residues or glycosylation sites. An upper band alone cannot establish a modification or explain its apparent mass.
DMRTA2 is annotated as nuclear. A nuclear-enriched sample is consistent with that location; keep the fraction consistent when comparing samples.
Compare candidate bands with the predicted 53.4 kDa mass and the annotated nuclear location. The supplied features do not identify an observed band, alternative sequence, or modification that would assign an unexpected band to DMRTA2.
The supplied features list no modified residues or glycosylation sites. An upper band alone cannot establish a modification or explain its apparent mass.
DMRTA2 is annotated as nuclear. A nuclear-enriched sample is consistent with that location; keep the fraction consistent when comparing samples.
Compare candidate bands with the predicted 53.4 kDa mass and the annotated nuclear location. The supplied features do not identify an observed band, alternative sequence, or modification that would assign an unexpected band to DMRTA2.
Boster reagents
DMRTA2 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-DMRTA2 Antibody (C-term)
Cat # A13203
The catalog reports one anti-DMRTA2 antibody for Western blotting: A13203, a C-terminal antibody with reported human, mouse, and zebrafish reactivity. Its product caption documents a blot, but no publication or independent validation evidence is supplied.
Which to pick: A13203 is the only listed option. Its WB image uses PC-3 cell, mouse testis, and zebrafish brain lysates at 35 µg per lane. These are tested examples; choose based on your sample and confirm performance under your conditions.
Source: BosterBio DMRTA2 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q96SC8.
- Human Protein Atlas. DMRTA2 tissue expression.
- PMC12186615 — target-verified WB comparison
- PMC10954651 — target-verified WB comparison
- PMC12293498 — target-verified WB comparison